Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep:198:230-237.
doi: 10.1016/j.puhe.2021.07.037. Epub 2021 Sep 3.

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel

Katarzyna Jabłońska  1 , Samuel Aballéa  2 , Mondher Toumi  3
Affiliations

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel

Katarzyna Jabłońska et al. Public Health. 2021 Sep.

Abstract

Objectives: This study aimed at estimating the real-life impact of vaccination on COVID-19 mortality, with adjustment for SARS-CoV-2 variants spread and other factors across Europe and Israel.

Study design: Time series analysis.

Methods: Time series analysis of the daily number of COVID-19 deaths was performed using non-linear Poisson mixed regression models. Variables such as variants' frequency, demographics, climate, health, and mobility characteristics of thirty-two countries between January 2020 and April 2021 were considered as potentially relevant adjustment factors.

Results: The analysis revealed that vaccination efficacy in terms of protection against deaths was 72%, with a lower reduction of the number of deaths for B.1.1.7 vs non-B.1.1.7 variants (70% and 78%, respectively). Other factors significantly related to mortality were arrivals at airports, mobility change from the prepandemic level, and temperature.

Conclusions: Our study confirms a strong effectiveness of COVID-19 vaccination based on real-life public data, although lower than expected from clinical trials. This suggests the absence of indirect protection for non-vaccinated individuals. Results also show that vaccination effectiveness against mortality associated with the B.1.1.7 variant is slightly lower than that with other variants. Lastly, this analysis confirms the role of mobility reduction, within and between countries, as an effective way to reduce COVID-19 mortality and suggests the possibility of seasonal variations in COVID-19 incidence.

Keywords: B.1.1.7 variant; COVID-19 mortality; Mobility; SARS-CoV-2 variants; VOC; Vaccination.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Fig. 1
Fig. 1
Mean SARS-CoV-2 variants proportions across countries, between January 2020 and April 2021. Mean proportions of variants were calculated based on daily data on variants proportions across observed strains used to form Nextstrain clades (variants), between 29 January 2020 and 15 April 2021.
Fig. 2
Fig. 2
Estimates of the vaccination effectiveness against mortality – main analysis and sensitivity analyses results. Abbreviations: 95% CI = 95% Confidence Interval. Assumptions of the analyses: Main analysis: time to onset = 7 days, time between symptoms onset and death = 14 days. Sensitivity analysis 1: time to onset = 14 days, time between symptoms onset and death = 14 days. Sensitivity analysis 2: time to onset = 14 days, time between symptoms onset and death = 7 days. Sensitivity analysis 3: time to onset = 7 days, time between symptoms onset and death = 7 days.
See this image and copyright information in PMC

References

    1. Liu Z., VanBlargan L.A., Rothlauf P.W., Bloyet L.-M., Chen R.E., Stumpf S., et al. Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv. 2020 2020.11.06.372037. - PMC - PubMed
    1. Hodcroft E.B. 2021. CoVariants: SARS-CoV-2 mutations and variants of interest.https://covariants.org/
    1. Rambaut A, Loman N, Pybus O. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. https://virological.org/t/preliminary-genomic-characterisation-of-an-eme... (accessed 15th March 2021).
    1. Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V., Giandhari J., et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020:2020. 12.21.20248640.
    1. Faria N., Claro I., Candido D., Franco L., Andrade P., Coletti T., et al. 2021. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings.https://virological.org/t/genomic-characterisation-of-an-emergent-sars-c...

Substances